FDA Approves Symplicity Spyral RDN Device to Treat Hypertension

Need an Account?

Content is available to registered users only. Registration is free.

Register now, or if you’ve already registered, log in.
News

FDA Approves Symplicity Spyral RDN Device to Treat Hypertension

Posted: 11/17/2023
Author:
Jason Wermers, CRTonline.org
Innovations Technology & Regulatory 2023 News Articles Hypertension Renal Denervation

The Symplicity Spyral Renal Denervation System received marketing approval from the U.S. Food and Drug Administration (FDA) to treat hypertension, Medtronic announced Friday.

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Need an Account?

News

FDA Approves Symplicity Spyral RDN Device to Treat Hypertension

Most Viewed Pages

Explore the Site

Stay Connected